| Title |
Author |
Type |
Date |
Words |
| Janssen, Clover pushing through with Philippine trials. |
|
|
Jan 15, 2021 |
649 |
| BioInvent and Cancer Research UK revise clinical development agreement for BI-1206. |
|
|
Jan 11, 2021 |
219 |
| BioInvent and Cancer Research UK revise clinical development agreement for BI-1206. |
|
|
Jan 11, 2021 |
224 |
| BioInvent and Cancer Research UK revise clinical development agreement for BI-1206. |
|
|
Jan 11, 2021 |
223 |
| Indian vaccine maker denies trial 'irregularities'. |
Sanjay Kumar |
|
Jan 9, 2021 |
766 |
| RedHill Biopharma says orphan lung disease therapy RHB-204 granted Fast Track designation by US Food and Drug Administration. |
|
|
Jan 8, 2021 |
476 |
| FDA okays Chinese firm's vaccine clinical trials. |
|
|
Jan 8, 2021 |
263 |
| China's Clover gets nod for Philippine trials. |
|
|
Jan 8, 2021 |
400 |
| RedHill Biopharma says orphan lung disease therapy RHB-204 granted Fast Track designation by US Food and Drug Administration. |
|
|
Jan 8, 2021 |
474 |
| Icon Supports Pfizer, BioNTech on the Investigational COVID-19 Vaccine Trial. |
|
|
Jan 5, 2021 |
314 |
| RedHill Biopharma receives encouraging safety and efficacy data from Opaganib Phase 2 COVID-19 study. |
|
Clinical report |
Jan 4, 2021 |
316 |
| RedHill Biopharma receives encouraging safety and efficacy data from Opaganib Phase 2 COVID-19 study. |
|
Clinical report |
Jan 4, 2021 |
312 |
| China's CanSino to submit COVID-19 vaccine trial results to Mexico next week. |
|
|
Dec 30, 2020 |
221 |
| China's CanSino to submit COVID-19 vaccine trial results to Mexico next week. |
|
|
Dec 30, 2020 |
225 |
| Korea shows little progress in vaccine development. |
|
|
Dec 23, 2020 |
629 |
| Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors. |
|
|
Dec 22, 2020 |
561 |
| France's Valneva to start clinical trials of its four COVID-19 vaccine candidate in UK sites. |
|
|
Dec 16, 2020 |
248 |
| France's Valneva to start clinical trials of its four COVID-19 vaccine candidate in UK sites. |
|
|
Dec 16, 2020 |
252 |
| Tests to start for new vaccine; CLINICAL TRIALS TO BEGIN IN NEWCASTLE. |
KATIE DICKINSON Reporter katie.dickinson@ncjmedia.co.uk |
|
Dec 16, 2020 |
333 |
| First Subject Dosed in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China. |
|
|
Dec 11, 2020 |
1179 |
| No more Philippine clinical trials for AstraZeneca. |
|
|
Dec 11, 2020 |
778 |
| Oxford/Astra first to publish final-stage vaccine trial results. |
|
|
Dec 9, 2020 |
674 |
| Clover Biopharmaceuticals Touts Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates. |
|
|
Dec 7, 2020 |
511 |
| DOST: Trials for China's Sinovac, Clover may start end-2020 or early 2021. |
|
|
Nov 27, 2020 |
380 |
| VBI Vaccines Touts Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection. |
|
|
Nov 19, 2020 |
505 |
| 2nd vaccine 94.5% effective, trial shows. |
MARTIN BAGOT |
|
Nov 17, 2020 |
180 |
| UK to lead final trials of vaccine. |
|
|
Nov 16, 2020 |
215 |
| 6,000 UK participants sought for final-stage Covid-19 vaccine trials. |
|
|
Nov 16, 2020 |
241 |
| 6,000 volunteers needed for final stage test of Covid vaccine; So far around 25,000 people in the UK have participated in vaccine trials. |
By, Neil Shaw |
|
Nov 16, 2020 |
636 |
| Johnson & Johnson Seeks 6,000 UK Participants For Vaccine Trial. |
|
|
Nov 16, 2020 |
641 |
| Medicago and GSK to begin final Covid-19 vaccine trials. |
|
|
Nov 13, 2020 |
333 |
| Brazil allows trials of Chinese vaccine to resume. |
|
|
Nov 12, 2020 |
515 |
| China's Sinovac denies safety issues of its COVID-19 vaccine candidate as reason for Brazil's decision to halt trials. |
|
|
Nov 10, 2020 |
217 |
| China's Sinovac denies safety issues of its COVID-19 vaccine candidate as reason for Brazil's decision to halt trials. |
|
|
Nov 10, 2020 |
221 |
| Brazil halts trials of Chinese Covid-19 vaccine. |
|
|
Nov 10, 2020 |
574 |
| AstraZeneca's COVID-19 vaccine deliveries on hold as it awaits trial data. |
|
|
Nov 5, 2020 |
277 |
| AstraZeneca's COVID-19 vaccine deliveries on hold as it awaits trial data. |
|
|
Nov 5, 2020 |
281 |
| Dr. Reddy's Partners On Sputnik V vaccine Clinical Trials in India. |
|
|
Oct 29, 2020 |
350 |
| Precision NanoSystems Will Receive CDN 18.2m from the government of Canada to Develop an RNA Vaccine for COVID-19. |
|
|
Oct 26, 2020 |
299 |
| Cyclacel Pharmaceuticals presents Phase 1 data on fadraciclib. |
|
|
Oct 26, 2020 |
330 |
| RedHill Biopharma presents new data from Talicia Phase 3 studies. |
|
|
Oct 26, 2020 |
367 |
| US gives full approval to antiviral remdesivir to treat Covid-19. |
|
|
Oct 23, 2020 |
542 |
| Merck Touts Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine. |
|
|
Oct 22, 2020 |
906 |
| Mereo BioPharma announces FDA clearance for Phase 1b/2 study of etigilimab. |
|
|
Oct 19, 2020 |
198 |
| 'Change of mind:' China-based pharma firm will not join vaccine trials. |
|
|
Oct 17, 2020 |
305 |
| RegeneRx Biopharmaceuticals likely to complete phase three clinical trial for dry eye syndrome in November 2020. |
|
|
Oct 15, 2020 |
161 |
| RegeneRx Biopharmaceuticals likely to complete phase three clinical trial for dry eye syndrome in November 2020. |
|
|
Oct 15, 2020 |
165 |
| China's Sinovac hurdles initial stage of screening for clinical trials in Philippines. |
|
|
Oct 15, 2020 |
307 |
| Johnson & Johnson second on the list of COVID-19 vaccine setbacks, markets remain calm. |
|
|
Oct 14, 2020 |
505 |
| Johnson & Johnson second on the list of COVID-19 vaccine setbacks, markets remain calm. |
|
|
Oct 14, 2020 |
507 |
| Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis. |
|
|
Oct 13, 2020 |
387 |
| Gilead, Galapagos presents data from Phase 2b/3 trial of filgotinib. |
|
|
Oct 12, 2020 |
563 |
| 3 int'l COVID-19 vaccine makers gunning for Phase 3 clinical trials in PH. |
|
|
Oct 8, 2020 |
354 |
| ARCA Biopharma announces FDA approval of IND application for AB201. |
|
|
Oct 7, 2020 |
342 |
| IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat. |
|
|
Oct 6, 2020 |
273 |
| CTI BioPharma to submit NDA for potential accelerated approval of pacritinib for Myelofibrosis Patients with Severe Thrombocytopenia. |
|
|
Sep 30, 2020 |
179 |
| CTI BioPharma to submit NDA for potential accelerated approval of pacritinib for Myelofibrosis Patients with Severe Thrombocytopenia. |
|
|
Sep 30, 2020 |
175 |
| COVAXX begins Phase 1 clinical trial of COVID-19 vaccine UB-612 in Taiwan. |
|
|
Sep 29, 2020 |
253 |
| COVAXX begins Phase 1 clinical trial of COVID-19 vaccine UB-612 in Taiwan. |
|
|
Sep 29, 2020 |
249 |
| Egypt's health minister takes part in clinical trial of Chinese coronavirus vaccine candidate. |
Egypt Today staff |
|
Sep 28, 2020 |
341 |
| India's vaccine capacity will help 'all humanity' - Modi. |
|
|
Sep 27, 2020 |
688 |
| Clover Biopharmaceuticals Touts Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate. |
|
|
Sep 25, 2020 |
683 |
| Spend 94 billion won this year to develop homegrown COVID-19 vaccine. |
|
|
Sep 25, 2020 |
296 |
| Sinovac's Coronavac, SARS-CoV-2 Vaccine, Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children. |
|
|
Sep 24, 2020 |
307 |
| Sinovac Starts Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey. |
|
|
Sep 22, 2020 |
485 |
| Seattle Genetics, Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020. |
|
|
Sep 21, 2020 |
584 |
| Seattle Genetics, Genmab presents data from innovaTV 204 phase 2 trial. |
|
|
Sep 21, 2020 |
482 |
| Genentech presents new data from multiple Phase III studies of Tecentriq in TNBC. |
|
|
Sep 20, 2020 |
452 |
| Astellas Pharma, Seattle Genetics announce Padcev trial meets primary endpoint. |
|
|
Sep 18, 2020 |
216 |
| I-MAB, MorphoSys announce FDA clearance of IND for MOR210/TJ210. |
|
|
Sep 17, 2020 |
195 |
| Bahrain crown prince volunteers in Covid-19 vaccine trial. |
Arab News |
|
Sep 16, 2020 |
218 |
| Phase 3 Testing: Is The Vaccine Safe? |
Claudia Z |
|
Sep 15, 2020 |
600 |
| AstraZeneca, Oxford University Resume Covid-19 Vaccine Trials In UK. |
|
|
Sep 14, 2020 |
267 |
| Vaxart announces FDA clearance of IND application for oral COVID-19 vaccine. |
|
|
Sep 14, 2020 |
181 |
| 7 firms sign CDA for vaccine trial candidates. |
|
|
Sep 10, 2020 |
391 |
| AstraZeneca says COVID-19 vaccine trial paused due to unexplained illness of participant. |
ANI |
|
Sep 9, 2020 |
563 |
| Genentech initiates Phase III clinical trial programs for fenebrutinib, Ocrevus. |
|
|
Sep 9, 2020 |
539 |
| Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer. |
|
|
Sep 9, 2020 |
240 |
| Strongbridge Biopharma announces 'positive' results from Phase 3 RECORLEV study. |
|
Clinical report |
Sep 8, 2020 |
171 |
| Strongbridge Biopharma expects to submit RECORLEV NDA in 1Q21. |
|
Clinical report |
Sep 8, 2020 |
172 |
| South Korea to spend W171 billion to develop COVID-19 vaccine. |
|
|
Sep 4, 2020 |
265 |
| Florence Healthcare Supports Pfizer's COVID-19 Vaccine Clinical Trials with Extensive Connectivity Platform. |
|
|
Sep 3, 2020 |
263 |
| Sanofi And Glaxo Aim For December Start For Phase 3 Of Vaccine Trial. |
|
|
Sep 3, 2020 |
188 |
| TAKE YOUR BEST SHOT: The whole world wants a vaccine, but countries will naturally try to secure a supply for themselves first. |
Regalado, Antonio |
|
Sep 1, 2020 |
2302 |
| Taiwan approves human trials for 2nd coronavirus vaccine. |
|
|
Aug 28, 2020 |
245 |
| Scancell Holdings consortium gets government backing for Covid trial. |
|
|
Aug 28, 2020 |
283 |
| Taiwan's 1st coronavirus vaccine on track for Phase II trials in Nov. |
|
|
Aug 27, 2020 |
343 |
| BeiGene to develop, manufacture Singlomics anti-COVID-19 antibodies. |
|
Clinical report |
Aug 27, 2020 |
215 |
| Mereo BioPharma initiates Phase 1b/2 trial with alvelestat in COVID-19. |
|
|
Aug 25, 2020 |
289 |
| Matinas BioPharma publishes data from Phase 1 EnACT study of MAT2203 to treat cryptococcal meningitis. |
|
|
Aug 21, 2020 |
450 |
| Taiwan's 1st coronavirus vaccine approved for human trials. |
|
|
Aug 18, 2020 |
327 |
| A shot for humanity: UAE's vaccine trial for Covid-19. |
Reach by Gulf News |
|
Aug 14, 2020 |
1056 |
| PH in talks with 16 other vaccine developers for COVID-19, not just Russia -- DOH. |
|
|
Aug 14, 2020 |
869 |
| A shot for humanity: Join UAE's vaccine trial for Covid-19. |
Reach by Gulf News |
|
Aug 13, 2020 |
977 |
| PH panel meets with Russian vaccine manufacturer to discuss clinical trials. |
|
|
Aug 12, 2020 |
375 |
| DOST to meet Russian vaccine maker on possible PH participation in clinical trials. |
|
|
Aug 12, 2020 |
484 |
| Gilead submits NDA to FDA for Veklury for COVID-19 treatment. |
|
Clinical report |
Aug 10, 2020 |
224 |
| US conducts further clinical trial for remdesivir as COVID-19 treatment. |
|
|
Aug 7, 2020 |
525 |
| RedHill Biopharma Phase 2/3 COVID-19 study approved in Mexico. |
|
|
Aug 6, 2020 |
220 |
| Moderna board member steps down to avoid conflict of interest in COVID-19 clinical trial. |
|
|
Jul 31, 2020 |
188 |
| Moderna board member steps down to avoid conflict of interest in COVID-19 clinical trial. |
|
|
Jul 31, 2020 |
192 |
| RedHill Biopharma initiates global Phase 2/3 study for COVID-19. |
|
|
Jul 30, 2020 |
196 |
| Genentech Shares Disappointing News on Phase III COVACTA Trial of Actemra in Hospitalized Patients with Severe COVID-19 Associated Pneumonia. |
|
|
Jul 29, 2020 |
915 |
| Cue Biopharma begins dosing Cohort 5 in Phase 1 trial of CUE--101. |
|
|
Jul 28, 2020 |
290 |
| Moderna's BARDA agreement expanded to support Phase 3 trial of COVID vaccine. |
|
|
Jul 26, 2020 |
386 |
| Moderna's BARDA agreement expanded to support larger Phase 3 COVID vaccine trial. |
|
|
Jul 26, 2020 |
386 |
| Medidata Supports Moderna's COVID-19 Vaccine Clinical Trials. |
|
|
Jul 23, 2020 |
257 |
| RedHill Biopharma submits CTAs in Brazil, Mexico for Phase 2/3 COVID-19 program. |
|
|
Jul 22, 2020 |
344 |
| Biogen to initiate Phase 4 study of SPINRAZA in patients treated with Zolgensma. |
|
|
Jul 21, 2020 |
377 |
| 9 Meters Biopharma doses first patients in Phase 1b/2a clinical trial in SBS. |
|
|
Jul 21, 2020 |
213 |
| Coronavirus: Moderna surges as coronavirus vaccine trial takes another step forward. |
|
|
Jul 16, 2020 |
504 |
| UAE begins world's first phase 3 trial of inactivated Covid vaccine. |
|
|
Jul 16, 2020 |
1003 |
| RedHill Biopharma receives approval for Phase 2/3 COVID-19 study. |
|
|
Jul 16, 2020 |
350 |
| Coronavirus: Moderna surges as coronavirus vaccine trial takes another step forward. |
|
|
Jul 16, 2020 |
502 |
| Dynavax announces first patients dosed in Phase 1 trial of Medicago's vaccine. |
|
|
Jul 14, 2020 |
277 |
| Genentech says Phase IIIb STASEY study data reinforces Hemlibra safety profile. |
|
|
Jul 13, 2020 |
546 |
| Biogen initiates new phase 3 study of BAN2401 in preclinical AD. |
|
|
Jul 13, 2020 |
184 |
| Genentech Says New Data from Phase IIIb Study Reinforces Safety Profile of Hemlibra in People with Hemophilia A. |
|
|
Jul 13, 2020 |
681 |
| DRAP urged to take emergency steps for approving clinical trials of proposed COVID-19 vaccine. |
|
|
Jul 10, 2020 |
761 |
| DRAP urged to take emergency steps for approving clinical trials of proposed COVID-19 vaccine. |
|
|
Jul 9, 2020 |
681 |
| Brazil to become testing ground for coronavirus vaccine. |
|
|
Jul 8, 2020 |
732 |
| Gilead starts Phase 1a trial of inhaled remdesivir in healthy volunteers. |
|
|
Jul 8, 2020 |
216 |
| Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial. |
|
|
Jul 6, 2020 |
827 |
| Seattle Genetics reports 'positive' results from Phase 2 tisotumab vedotin trial. |
|
Financial report |
Jun 29, 2020 |
231 |
| Companies Submit IND To FDA For Coronavirus Stem Cell Trial. |
|
|
Jun 29, 2020 |
397 |
| RedHill Biopharma receives approval for COVID-19 Phase 2/3 study with opaganib. |
|
Report |
Jun 29, 2020 |
222 |
| Stirling company to make virus vaccine; Symbiosis will supply trials. |
ALASTAIR MCNEILL |
|
Jun 24, 2020 |
420 |
| Pfizer Starts Four Phase 3 Clinical Trials for Investigational Vaccines. |
|
|
Jun 23, 2020 |
673 |
| Seattle Genetics Initiates Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates. |
|
|
Jun 22, 2020 |
523 |
| Pfizer announces initiation of four Phase 3 investigational vaccine studies. |
|
|
Jun 22, 2020 |
153 |
| TransCelerate Expands COVID-19 Clinical Trial Data Sharing to Include All Biopharma Companies and BioMedical Research Institutions. |
|
|
Jun 17, 2020 |
400 |
| Cue Biopharma says enrollment remains on schedule in Phase 1 trial of CUE-101. |
|
|
Jun 15, 2020 |
452 |
| Moderna expects to begin Phase Phase 3 study of COVID-19 vaccine in July. |
|
|
Jun 11, 2020 |
246 |
| China's Sinovac Inks Deal with Brazil's Butantan for the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III. |
|
|
Jun 11, 2020 |
590 |
| RedHill Biopharma submits COVID-19 CTA for Phase 2/3 study of opaganib. |
|
Clinical report |
Jun 10, 2020 |
344 |
| PHL to join Sinovac clinical trials for Covid-19 vaccine. |
|
|
Jun 9, 2020 |
373 |
| Chinese biopharm firm among PH's collaborators to develop COVID-19 vaccine. |
|
|
Jun 9, 2020 |
295 |
| Baguio nurse joins WHO trials for COVID-19 treatment. |
|
|
Jun 6, 2020 |
210 |
| Gilead, Galapagos announce Week 52 results from Phase 3 FINCH 1, FINCH 3 studies. |
|
|
Jun 4, 2020 |
153 |
| Can-Fite BioPharma concludes meeting with EMA on Phase 3 Namodenoson development. |
|
|
Jun 4, 2020 |
253 |
| Gilead Shows Results from Phase 3 Trial of Remdesivir in Patients with Moderate COVID-19. |
|
|
Jun 2, 2020 |
892 |
| Gilead Sciences, Roche to study remdesivir/Actemra combination in coronavirus patients. |
|
|
May 29, 2020 |
232 |
| Genocea presents updated long-term data from GEN-009 Phase 1/2a trial. |
|
|
May 29, 2020 |
335 |
| Gilead Sciences, Roche to study remdesivir/Actemra combination in coronavirus patients. |
|
|
May 29, 2020 |
230 |
| Genentech Starts Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients with Severe COVID-19 Pneumonia. |
|
|
May 28, 2020 |
1016 |
| Genentech, Gilead initiate Phase III clinical trial of Actemra plus remdesivir. |
|
|
May 28, 2020 |
340 |
| RedHill Biopharma aims to enroll up to 40 patients in Phase 2a study of opaganib. |
|
Clinical report |
May 27, 2020 |
184 |
| COVID-19 vaccine clinical trials set in 2021. |
|
|
May 21, 2020 |
350 |
| Galapagos, Gilead report Phase 2B/3 results from filgotinib study. |
|
|
May 20, 2020 |
168 |
| Cue Biopharma to present preclinical data on CUE-102/A02, CUE-102/A24. |
|
|
May 18, 2020 |
181 |
| Transgene and BioInvent Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors. |
|
|
May 15, 2020 |
715 |
| ARCA Biopharma announces presentations of Gencaro clinical data. |
|
|
May 7, 2020 |
528 |
| RedHill Biopharma announces publication of results of Phase 3 study of Talicia. |
|
|
May 5, 2020 |
357 |
| Moderna submits IND to FDA for Phase 2 study of coronavirus vaccine. |
|
Report |
Apr 27, 2020 |
165 |
| LONDON MARKET EARLY CALL: Lower Call As Gilead Covid-19 Trial Fails. |
|
|
Apr 24, 2020 |
728 |
| LONDON MARKET OPEN: UK Retail Sales And Failed Gilead Trial Hit Stocks. |
|
|
Apr 24, 2020 |
1362 |
| Theravance Biopharma says first patient dosed in Phase 1 study of TD-0903. |
|
Report |
Apr 23, 2020 |
166 |
| AzurRx BioPharma expects interim data from Phase 2 combination trial in Q3. |
|
|
Apr 21, 2020 |
153 |
| RedHill Biopharma submits IND application for opaganib for COVID-19. |
|
Clinical report |
Apr 17, 2020 |
151 |
| OncoSec Medical partnering with Providence Cancer Institute on CORVax12 trial for potential coronavirus vaccine. |
|
|
Apr 7, 2020 |
394 |
| Geron says clinical trial activities being impacted by COVID-19 pandemic. |
|
|
Apr 2, 2020 |
250 |
| Matinas BioPharma pauses enrollment in ongoing clinical trials. |
|
|
Mar 31, 2020 |
421 |
| Can-Fite BioPharma implements interim analysis for Phase 3 Comfort trial. |
|
Clinical report |
Mar 30, 2020 |
201 |
| Arbutus Biopharma says COVID-19 may impact timelines on AB-729 trials. |
|
|
Mar 26, 2020 |
201 |
| Genentech initiates Phase III clinical trial of Actemra. |
|
|
Mar 19, 2020 |
264 |
| Moderna reports first participant dosed in Phase 1 coronavirus vaccine study. |
|
|
Mar 16, 2020 |
322 |
| Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19. |
|
|
Mar 4, 2020 |
639 |
| Governments, diagnostic companies and providers respond to coronavirus outbreak. |
Wilson, Linda |
|
Mar 1, 2020 |
2007 |
| Hansa Biopharma concludes enrollment in investigator-initiated phase 2 study in Anti-GBM patients. |
|
|
Jan 27, 2020 |
190 |
| Hansa Biopharma concludes enrollment in investigator-initiated phase 2 study in Anti-GBM patients. |
|
|
Jan 27, 2020 |
186 |
| Gilead Releases Disappointing Topline Results from Phase 2 ATLAS Study in Patients with Bridging Fibrosis and Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis. |
|
Clinical report |
Dec 19, 2019 |
382 |
| Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy. |
|
|
Dec 13, 2019 |
1038 |
| New England Journal of Medicine Publishes Positive Phase III Results for Genentech's Satralizumab in Neuromyelitis Optica Spectrum Disorder. |
|
|
Dec 3, 2019 |
1026 |
| Seattle Genetics, Astellas Forge Clinical Trial Collaboration with US Merck to Evaluate Enfortumab. |
|
|
Dec 3, 2019 |
456 |
| Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder. |
|
Clinical report |
Nov 21, 2019 |
1368 |
| NEC and Vaximm Forge Clinical Trial Collaboration. |
|
|
Nov 14, 2019 |
224 |
| RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA. |
|
|
Nov 12, 2019 |
1710 |
| Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer's Disease (CTAD) Congress on December 5, 2019. |
|
|
Nov 4, 2019 |
621 |
| Can-Fite BioPharma announces results from Namodenoson End-of-Phase 2 meeting. |
|
Financial report |
Oct 31, 2019 |
145 |
| Sutro Biopharma presents data from Phase I study of STRO-002. |
|
|
Oct 29, 2019 |
261 |
| RedHill Biopharma to present Phase 3 data on RHB-105, RHB-104. |
|
Clinical report |
Oct 28, 2019 |
122 |
| RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting. |
|
|
Oct 28, 2019 |
3169 |
| Genentech Touts Phase III PEMPHIX Study Results Showing Rituxan Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris. |
|
Clinical report |
Oct 23, 2019 |
133 |
| MorphoSys--MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China--14/10/2019. |
|
|
Oct 23, 2019 |
413 |
| Propanc Biopharma plans to advance clinical trials on lead cancer drug PRP. |
|
|
Oct 22, 2019 |
407 |
| Propanc Biopharma plans to advance clinical trials on lead cancer drug PRP. |
|
|
Oct 22, 2019 |
409 |
| MorphoSys--MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China--14/1/2019. |
|
|
Oct 17, 2019 |
413 |
| Can-Fite BioPharma completes enrollment in Phase II NASH study of Namodenoson. |
|
Clinical report |
Oct 15, 2019 |
169 |
| Principia Biopharma announces preliminary data of Phase 1/2 trial of PRN1008. |
|
|
Oct 15, 2019 |
276 |
| AzurRx BioPharma announces first patients dosed in MS1819-SD clinical trial. |
|
|
Oct 15, 2019 |
160 |
| Gilead Sciences and Galapagos NV reveal Week 52 data from the registrational Phase three FINCH 1 and FINCH 3 trials of filgotinib. |
|
|
Oct 14, 2019 |
178 |
| Gilead Sciences and Galapagos NV reveal Week 52 data from the registrational Phase three FINCH 1 and FINCH 3 trials of filgotinib. |
|
|
Oct 14, 2019 |
174 |
| I-Mab to expand ongoing phase II and III clinical trials of TJ202/MOR202 into China under fast-to-market development strategy. |
|
|
Oct 14, 2019 |
251 |
| I-Mab to expand ongoing phase II and III clinical trials of TJ202/MOR202 into China under fast-to-market development strategy. |
|
|
Oct 14, 2019 |
247 |
| MorphoSys, I-Mab Biopharma announce IND approval to initiate trials. |
|
|
Oct 14, 2019 |
197 |
| RedHill Biopharma reports results from MAP US Phase 3 study of RHB-104. |
|
Clinical report |
Oct 11, 2019 |
477 |
| Principia Biopharma announces preliminary data of PRN1008 from Phase 2 trial. |
|
|
Oct 10, 2019 |
441 |
| Geron announces first patient has been dosed in IMerge Phase 3 clinical trial. |
|
|
Oct 10, 2019 |
175 |
| Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites. |
|
|
Oct 2, 2019 |
362 |
| Japan Pharmaceuticals Industry - Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer -- 28/9/2019. |
|
|
Oct 2, 2019 |
1246 |
| Seattle Genetics (NASDAQ: SGEN) - Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer -- 29/9/2019. |
|
|
Oct 2, 2019 |
405 |
| Cue Biopharma initiates patient dosing in Phase 1 study of CUE-101. |
|
|
Sep 30, 2019 |
165 |
| RegeneRx: Phase 3 ARISE-3 trial 'progressing smoothly' according to plan. |
|
|
Sep 30, 2019 |
333 |
| Seattle Genetics, Astellas announce results from Phase 1 clinical trial EV-103. |
|
|
Sep 29, 2019 |
294 |
| Seattle Genetics presents data from single arm Phase 2 MOUNTAINEER trial. |
|
|
Sep 29, 2019 |
117 |
| AzurRx BioPharma announces results from Phase 2 trial with MS1819. |
|
|
Sep 25, 2019 |
374 |
| Biogen to initiate DEVOTE clinical trial evaluating higher dose of SPINRAZA. |
|
|
Sep 18, 2019 |
275 |
| Mereo BioPharma expects 12-month data from Phase 2b ASTEROID trial in Q4. |
|
|
Sep 17, 2019 |
122 |
| Theravance Biopharma announces 'positive' results from Phase 1 trial of TD-8236. |
|
|
Sep 9, 2019 |
437 |
| Infinity Pharmaceuticals initiates IPI-549, MARIO-3 trials. |
|
|
Sep 4, 2019 |
159 |
| Genentech Presents Positive Phase III Study Results for One-dose Xofluza in Children with the Flu. |
|
Clinical report |
Sep 3, 2019 |
765 |
| Nabriva Shares Volatile As Biopharma Updates FDA Filing Timeline. |
|
Chronology |
Aug 16, 2019 |
457 |
| AzurRx BioPharma: Phase II OPTION study of MS1819-SD progressing as planned. |
|
|
Aug 13, 2019 |
155 |
| Geron starts Phase 3 portion of IMerge to evaluate imetelstat. |
|
|
Aug 8, 2019 |
298 |
| RegeneRx Biopharmaceuticals admits first EB patient in single-blinded, phase 2 clinical trial of candidate RGN-137. |
|
|
Aug 6, 2019 |
323 |
| RegeneRx Biopharmaceuticals admits first EB patient in single-blinded, phase 2 clinical trial of candidate RGN-137. |
|
|
Aug 6, 2019 |
319 |
| Arbutus Biopharma expects results from Phase 1a/1b trial of AB-506 in 1H20. |
|
|
Aug 5, 2019 |
138 |
| TRACON, I-Mab Biopharma dose first patient in Phase 1 trial of TJD5. |
|
|
Aug 1, 2019 |
197 |
| Dosing Begins In Phase 1/2a Study Of Treatment For Dry-AMD. |
|
Clinical report |
Jul 29, 2019 |
520 |
| BioCardia 'validated' by biopharma giant AstraZeneca in exclusive development agreement. |
|
|
Jul 29, 2019 |
135 |
| BioCardia 'validated' by biopharma giant AstraZeneca in exclusive development agreement. |
|
|
Jul 29, 2019 |
135 |
| US FDA authorises Immix Biopharma to proceed with IMX-110 phase 1b/2a clinical trial expansion. |
|
|
Jul 24, 2019 |
235 |
| US FDA authorises Immix Biopharma to proceed with IMX-110 phase 1b/2a clinical trial expansion. |
|
|
Jul 24, 2019 |
231 |
| Theravance Biopharma presents new data from Phase 2 study of ampreloxetine. |
|
|
Jul 22, 2019 |
116 |
| Propanc Biopharma provides update on PRP clinical trial application and reverse common stock split. |
|
|
Jul 16, 2019 |
258 |
| Propanc Biopharma provides update on PRP clinical trial application and reverse common stock split. |
|
|
Jul 16, 2019 |
254 |
| Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split. |
|
|
Jul 16, 2019 |
376 |
| Mereo BioPharma, FDA discuss design outline for Phase 2 trial of navicixizumab. |
|
|
Jul 15, 2019 |
320 |
| Array BioPharma Inc updates results of Phase 3 BEACON CRC trial of BRAFTOVI MEKTOVI and ERBITUX in patients with advanced colorectal cancer. |
|
|
Jul 8, 2019 |
315 |
| Array BioPharma Inc updates results of Phase 3 BEACON CRC trial of BRAFTOVI MEKTOVI and ERBITUX in patients with advanced colorectal cancer. |
|
|
Jul 8, 2019 |
311 |
| AzurRx BioPharma begins Initiation of phase 2 clinical study for MS1819-SD. |
|
Clinical report |
Jul 8, 2019 |
155 |
| Sinovac Biotech (NASDAQ: SVA) - Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectiou -- 16/4/2019. |
|
|
Jul 4, 2019 |
514 |
| Bioinvent granted authorisation by US FDA to proceed with Phase I/IIa clinical trial of an immune-modulatory anti-FcI[superscript three]RllB antibody. |
|
|
Jul 2, 2019 |
219 |
| Bioinvent granted authorisation by US FDA to proceed with Phase I/IIa clinical trial of an immune-modulatory anti-FcI[superscript three]RllB antibody. |
|
|
Jul 2, 2019 |
215 |
| Gilead intends to submit NDA for filgotinib to FDA this year. |
|
|
Jul 1, 2019 |
116 |
| Arbutus Biopharma receives clearance to initiate Phase 1a/1b trial of AB-729. |
|
|
Jun 20, 2019 |
137 |
| Theravance Biopharma reports new data from Phase 2 clinical study of TD-9855. |
|
Clinical report |
Jun 18, 2019 |
125 |
| Sutro Biopharma announces interim Phase 1 safety data for STRO-001. |
|
|
Jun 16, 2019 |
105 |
| Genentech Touts Positive Topline Results for Gazyva in Phase II Lupus Nephritis Study. |
|
|
Jun 12, 2019 |
532 |
| Genentech Phase II study of Gazyva met primary, key secondary endpoints. |
|
|
Jun 11, 2019 |
142 |
| Genentech Presents Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia. |
|
|
Jun 6, 2019 |
115 |
| Seattle Genetics (NASDAQ: SGEN) - Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS[R] (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting -- 3/6/2019. |
|
|
Jun 6, 2019 |
1242 |
| Vaccitech begins Phase 2b clinical study of MVA-NP+M1 universal flu vaccine (VTP-100) in Belgium and concludes recruitment in Australia. |
|
|
Jun 5, 2019 |
294 |
| Vaccitech begins Phase 2b clinical study of MVA-NP+M1 universal flu vaccine (VTP-100) in Belgium and concludes recruitment in Australia. |
|
|
Jun 5, 2019 |
290 |
| Genentech reveals results of two phase III Xolair studies. |
|
|
Jun 4, 2019 |
194 |
| Genentech reveals results of two phase III Xolair studies. |
|
|
Jun 4, 2019 |
190 |
| BioInvent submits IND with US FDA for Phase I/IIa trial of anti-FcI[superscript three]RIIB antibody. |
|
|
Jun 3, 2019 |
252 |
| BioInvent submits IND with US FDA for Phase I/IIa trial of anti-FcI[superscript three]RIIB antibody. |
|
|
Jun 3, 2019 |
248 |
| Genentech: POLYP 1, POLYP 2 Phase III trials met co-primary, secondary endpoints. |
|
|
Jun 3, 2019 |
184 |
| Genentech: POLYP 1, POLYP 2 Phase III trials met co-primary, secondary endpoints. |
|
|
Jun 3, 2019 |
201 |
| Seattle Genetics, Astellas announce data from cohort of EV-201 trial. |
|
|
Jun 3, 2019 |
516 |
| Seattle Genetics announces additional analyses of ECHELON-1, ECHELON-2 trials. |
|
|
Jun 3, 2019 |
884 |
| Array BioPharma to present data from Phase 3 COLUMBUS trial at ASCO. |
|
|
May 29, 2019 |
155 |
| Ansun Biopharma admits first patient with parainfluenza infection in Phase 3 Clinical Trial of DAS181. |
|
|
May 29, 2019 |
285 |
| Ansun Biopharma admits first patient with parainfluenza infection in Phase 3 Clinical Trial of DAS181. |
|
|
May 29, 2019 |
281 |
| Ansun Biopharma enrols first patient in phase three DAS181 clinical trial. |
|
|
May 29, 2019 |
217 |
| Ansun Biopharma enrols first patient in phase three DAS181 clinical trial. |
|
|
May 29, 2019 |
213 |
| Theravance Biopharma reports data from Phase 1b study of JAK inhibitor TD-1473. |
|
Report |
May 21, 2019 |
132 |
| Array BioPharma: Phase 3 BEACON CRC trial met primary endpoints. |
|
|
May 21, 2019 |
122 |
| Encouraging Results From OpRegen Phase 1/2a Clinical Study Presented. |
|
Clinical report |
May 20, 2019 |
316 |
| RegeneRx enrolls first patient in RegeneRx JV phase 3 dry eye trial. |
|
|
May 13, 2019 |
191 |
| CEL-SCI says length of Phase 3 study could be sign of Multikine's efficacy. |
|
|
May 8, 2019 |
580 |
| Sinovac Biotech Ltd. (NASDAQ: SVA) - Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectiou -- 16/4/2019. |
|
|
May 8, 2019 |
493 |
| RedHill Biopharma submits NDA to FDA for Talicia for H. pylori Infection. |
|
|
May 7, 2019 |
123 |
| Sinovac Biotech Ltd. (NASDAQ: SVA) - Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectiou -- 16/4/2019. |
|
|
May 2, 2019 |
493 |
| Forty Seven expands agreement with Genentech for third 5F9 with rituximab trial. |
|
|
Apr 26, 2019 |
146 |
| Sinovac Biotech Ltd. (NASDAQ: SVA) - Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectiou -- 16/4/2019. |
|
|
Apr 25, 2019 |
493 |
| Hansa Biopharma announces receipt of Ethics and Regulatory Committee clearance to commence phase 2 Study of Imlifidase in Guillain BarrA(c) Syndrome. |
|
|
Apr 16, 2019 |
314 |
| Hansa Biopharma announces receipt of Ethics and Regulatory Committee clearance to commence phase 2 Study of Imlifidase in Guillain BarrA(c) Syndrome. |
|
|
Apr 16, 2019 |
315 |
| Hansa Biopharma announces receipt of Ethics and Regulatory Committee clearance to commence phase 2 Study of Imlifidase in Guillain BarrA(c) Syndrome. |
|
|
Apr 16, 2019 |
310 |
| Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain BarrA(c) Syndrome. |
|
|
Apr 16, 2019 |
790 |
| Hansa Biopharma wins Ethics and Regulatory clearance in Europe to begin Phase 2 Study of Imlifidase in Guillain BarrA(c) Syndrome. |
|
|
Apr 15, 2019 |
262 |
| Hansa Biopharma wins Ethics and Regulatory clearance in Europe to begin Phase 2 Study of Imlifidase in Guillain BarrA(c) Syndrome. |
|
|
Apr 15, 2019 |
258 |
| LSK BioPharma & Jiangsu Hengrui Medicine partnership wins US FDA clearance to commence Phase 3 clinical trial in advanced HCC. |
|
|
Apr 9, 2019 |
277 |
| Gilead submits supplemental NDA for once-daily Descovy for HIV PrEP. |
|
|
Apr 5, 2019 |
353 |
| Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer. |
|
|
Apr 2, 2019 |
526 |
| Seattle Genetics and Astellas Tout Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer. |
|
|
Apr 1, 2019 |
731 |
| Seattle Genetics and Astellas announce positive top-line results from enfortumab vedotin cancer trial. |
|
|
Mar 29, 2019 |
291 |
| Seattle Genetics and Astellas announce positive top-line results from enfortumab vedotin cancer trial. |
|
|
Mar 29, 2019 |
287 |
| Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial. |
|
|
Mar 29, 2019 |
373 |
| Seattle Genetics completes enrollment in pivotal innovaTV 204 phase 2 trial. |
|
|
Mar 29, 2019 |
117 |
| Seattle Genetics, Astellas Pharma announce topline results of EV-201 trial. |
|
|
Mar 28, 2019 |
266 |
| Hansa Biopharma announces receipt of ethics and regulatory clearance to start phase 2 Study of imlifidase in Acute Antibody Mediated Rejection in kidney transplantation. |
|
Report |
Mar 27, 2019 |
306 |
| Hansa Biopharma announces receipt of ethics and regulatory clearance to start phase 2 Study of imlifidase in Acute Antibody Mediated Rejection in kidney transplantation. |
|
Report |
Mar 27, 2019 |
302 |
| Biogen, Eisai discontinue ENGAGE and EMERGE Phase 3 trials. |
|
|
Mar 21, 2019 |
252 |
| MorphoSys--MorphoSys AG: MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL--7/3/2019. |
|
|
Mar 20, 2019 |
547 |
| MorphoSys, I-Mab Biopharma initiate phase 2 study of TJ202 for multiple myeloma. |
|
|
Mar 19, 2019 |
118 |
| Bahamas Approves Stem Cell Trial In Musculoskeletal Conditions. |
|
|
Mar 18, 2019 |
571 |
| Bahamas Approves Stem Cell Trial In Musculoskeletal Conditions. |
|
|
Mar 18, 2019 |
571 |
| TaiwanJ Pharmaceuticals signs JKB-122 licensing and co-development agreement with Newsoara Biopharma for Asia. |
|
|
Mar 11, 2019 |
211 |
| TaiwanJ Pharmaceuticals signs JKB-122 licensing and co-development agreement with Newsoara Biopharma for Asia. |
|
|
Mar 11, 2019 |
207 |
| ARCA Biopharma announces publication of BEST, HF-ACTION trial data. |
|
|
Mar 6, 2019 |
295 |
| Principia Biopharma announces data from Phase 2 Pemphigus Vulgaris trial. |
|
|
Mar 3, 2019 |
363 |
| Principia Biopharma presents Phase 1 PRN2246 data at ACTRIMS. |
|
|
Mar 1, 2019 |
286 |
| AC Immune announces anti-tau monoclonal antibody entering second Phase 2 trial. |
|
|
Feb 20, 2019 |
238 |
| ARCA Biopharma announces FDA agreement for Phase 3 PRECISION-AF trial. |
|
|
Feb 20, 2019 |
298 |
| AzurRx BioPharma doses first patients in Phase 2 OPTION study. |
|
|
Feb 20, 2019 |
109 |
| Gilead Sciences reveals data from the phase three Stellar-four study of selonsertib. |
|
|
Feb 13, 2019 |
226 |
| Eiger submits lonafarnib IND with US FDA for the treatment of Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies. |
|
|
Dec 4, 2018 |
287 |
| Eiger submits lonafarnib IND with US FDA for the treatment of Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies. |
|
|
Dec 4, 2018 |
283 |
